Precision and Protection: Inside Cone Health’s Robotic Compounding Program
July 2nd 2025Pharmacy leaders from Cone Health discuss how robotic compounding technologies have improved safety, accuracy, and reliability in hazardous and sterile medication preparation across oncology and acute care settings.
Watch
FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma
Published: July 2nd 2025 | Updated: July 2nd 2025The treatment becomes the first approved BCMAxCD3 bispecific antibody with the potential to achieve biweekly or monthly dosing in patients with relapsed/refractory multiple myeloma.
Read More
Integrating Emotional Healing Through Psychedelics Into Everyday Oncology Practice
July 2nd 2025Manish Agrawal, MD, discusses the implementation of psilocybin-assisted therapy in a community cancer setting, highlighting its potential to provide sustained relief from depression and anxiety and its significant efficacy advantage over selective serotonin reuptake inhibitors for patients with cancer.
Watch
Case-Based Insights on Managing Steroid-Refractory cGVHD After Haploidentical Transplant
July 1st 2025Gianni Scappaticci, PharmD, BCOP, outlines a personalized, evidence-based approach to managing steroid-refractory chronic graft-versus-host disease (cGVHD) in a post–haploidentical transplant patient, highlighting the rationale for using ruxolitinib, belumosudil, or their combination based on disease progression and fibrotic features.
Watch
An Overview of Intravenous Iron in Heart Failure and the FAIR-HF2 Trial
Host Craig Beavers sits down with Kazuhiko Kido, PharmD, a clinical associate professor at the West Virginia University School of Pharmacy, to discuss intravenous iron and its use in patients with heart failure.
Listen
Navigating Rilonacept Therapy: Dose Adjustments, Discontinuation, and Patient Support Strategies
Pharmacists and clinicians collaborate to carefully manage rilonacept therapy.
Watch
ASCO 2025: Using Discrete Choice Data to Support Personalized Pharmacy Counseling in ALK+ NSCLC
June 30th 2025Christopher Danes, PhD, discusses how discrete choice experiment data reveal key differences in patient and caregiver treatment preferences for ALK-positive (ALK+) non–small cell lung cancer (NSCLC) and how pharmacists can use these insights to guide shared decision-making, optimize supportive care, and personalize adherence strategies.
Read More